The research landscape for the human epidermal growth factor family of receptors has expanded with the discovery of their additional diverse roles in cancer. Extensive study of their function in aiding carcinogenesis and resistance to therapy is characterized and described in a number of reports1–3. In pancreatic cancer, the epidermal growth factor receptor (EGFR) is expressed in 30–90% of patients with pancreatic ductal adenocarcinoma (PDAC)4–6, marking aggressive disease with poor survival rates. EGFR has notably contributed to its early carcinogenesis from normal pancreatic epithelia, which transitions to neoplasms of pancreatic intraepithelial (PanIN) and finally, forming PDAC7.